Bloomberg the Company

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: London
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma


36.500 GBp 0.0000.00%

As of 11:35:05 ET on 01/30/2015.

Snapshot for IXICO PLC (IXI)

Open: 36.500 Day's Range: 36.500 - 36.500 Volume: 3,659
Previous Close: 36.500 52wk Range: 34.500 - 85.500 1-Yr Rtn: -46.72%

Stock Chart for IXI

No chart data available.
  • IXI:LN 36.500
  • 1D
  • 1M
  • 1Y
Interactive IXI Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for IXI

Current P/E Ratio (ttm) -
Estimated P/E(09/2014) -
Relative P/E vs. UKX -
Earnings Per Share (GBP) (ttm) -0.4100
Est. EPS (GBP) (09/2014) -0.1420
Est. PEG Ratio -
Market Cap (M GBP) 5.50
Shares Outstanding (M) 15.06
30 Day Average Volume 11,652
Price/Book (mrq) 1.1750
Price/Sale (ttm) 4.3181
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 02/27/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for IXI

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)

Company Profile & Key Executives for IXI

IXICO plc offers technologies for researching, diagnosing and treating serious diseases with a focus on neuro-degeneration. The technologies include medical image management and analysis products to assess the safety and efficacy of drugs in development. The Company's proprietary technologies TrialWire(tm) and TrialTracker(tm) have been used in clinical trials of Alzheimer's treatments.

Derek HillChief Executive OfficerSusan Day LowtherChief Financial Officer
Jane WhitrowVP:Business Ops/SecretaryJohn HallVP:Business Development
More Company Profile & Key Executives for IXI

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil